Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database
Modern Rheumatology · 2024
DOI: 10.1093/mr/road031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Masayoshi Harigai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Products, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in adults aged ≥75 years with rheumatoid arthritis (RA).
Methods
We used a Japanese claims database from Medical Data Vision Co., Ltd (Tokyo, Japan) to perform a retrospective longitudinal population-based study in patients with RA who were prescribed b/tsDMARDs between 2014 and 2019. We calculated adjusted risk ratios (aRRs) for HIs in three age groups (<65, ≥65 and <75, and ≥75 years).
Results
Of 5506 patients, 2265 (41.1%) were <65 years, 1709 (31.0%) were 65–74 years, and 1532 (27.8%) were ≥75 years. Crude incidence rates (/100 person-years) of HIs were 3.99, 7.27, and 10.77, respectively. In the oldest group, aRRs (95% confidence interval) for HIs (b/tsDMARDs versus TCZ) were as follows: etanercept, 2.40 (1.24–4.61); adalimumab, 1.90 (0.75–4.83); golimumab, 1.21 (0.66–2.23); and abatacept, 0.89 (0.49–1.62). In the other age groups, the noticeable difference was a lower aRR of etanercept versus TCZ in the youngest group (0.30, 0.11–0.85).
Conclusion
In patients with RA aged ≥75 years, b/tsDMARDs have a similar risk of HIs to tocilizumab except for etanercept.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.
- Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.
- Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
- Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Yokohama, Japan.
- Medilead Inc., Tokyo Opera City Tower, Tokyo, Japan.
Zitieren
APA
Harigai, M., Fujii, T., Sakai, R., Igarashi, A., Shoji, A., Yamaguchi, H., Iwasaki, K., Makishima, M., Yoshida, A., Okada, N., Yamashita, K., & Kawahito, Y. (2024). Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database. Modern Rheumatology. https://doi.org/10.1093/mr/road031
Vancouver
Harigai M, Fujii T, Sakai R, Igarashi A, Shoji A, Yamaguchi H, et al. Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database. Modern Rheumatology. 2024. doi:10.1093/mr/road031
BibTeX
@article{Harigai2024,
author = {Harigai, Masayoshi and Fujii, Takao and Sakai, Ryoko and Igarashi, Ataru and Shoji, Ayako and Yamaguchi, Hiroko and Iwasaki, Katsuhiko and Makishima, Misako and Yoshida, Amika and Okada, Norihiro and Yamashita, Katsuhisa and Kawahito, Yutaka},
title = {Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/road031}
}
EUVIMED